Site
Search results
Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression
Sep 21, 2018 United States Study is one of five submitted to U.S. FDA by Janssen as part of its new drug application for esketamine nasal spray for treatment-resistant depression TITUSVILLE, N.J., Sept. 21, 2018 -- The Janssen Pharmaceutical Companies ...
Long-Term Phase 3 Study Shows Esketamine Nasal Spray Plus an Oral Antidepressant Delayed Time to Relapse in Patients with Treatment-Resistant Depression
May 31, 2018 United States A separate Phase 3 study provides evidence that esketamine was generally well tolerated with no new safety signals with up to 52 weeks of dosing for patients with treatment-resistant depression TITUSVILLE, N.J., May 31, 2018 -- ...
Janssen Submits European Marketing Authorisation Application for Esketamine Nasal Spray for Treatment-Resistant Depression
Oct 10, 2018 Belgium Data from five pivotal Phase 3 studies submitted as the basis for Marketing Authorisation Application for esketamine nasal spray BEERSE, Belgium-- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the ...
Janssen Phase 3 Study Programme of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Presented for the First Time in Europe
Jun 19, 2018 Belgium One long-term study provides evidence that esketamine delayed time to relapse A second study shows esketamine was generally well tolerated with no new safety signals BEERSE, Belgium-- The Janssen Pharmaceutical Companies of Johnson ...
New Phase 3 Data Show Esketamine Nasal Spray Demonstrated Rapid Improvements in Depressive Symptoms in Patients with Treatment-Resistant Depression
May 05, 2018 United States Study in adults with treatment-resistant depression marks the first time an antidepressant has achieved superiority in a clinical trial for major depressive disorder that included a newly initiated oral antidepressant in both ...
Newly Published Phase 2 Study Found Esketamine Demonstrated Significantly Rapid Improvements in Depressive Symptoms and Suicidality
Apr 16, 2018 United States Media Contact: Greg Panico 609-730-3061 (office) 908-240-2011 (mobile) Investor Contacts: Joseph J. Wolk 732-524-1142 (office) Lesley Fishman 732-524-3922 (office) If approved by the FDA, esketamine nasal spray would be the ...
Esketamine Phase 2 Data Published in JAMA Psychiatry Showed Significant Improvement of Depressive Symptoms in People with Treatment-Resistant Depression
Dec 28, 2017 United States TITUSVILLE, N.J., Dec. 28, 2017 /PRNewswire/-- Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that data from a Phase 2 clinical study of intranasal ...
FDA Advisory Committee Recommends Approval of SPRAVATO™ (esketamine) Nasal Spray CIII for Adults with Treatment-Resistant Depression
Feb 12, 2019 United States If approved, SPRAVATO™ will offer the first new mechanism of action in 30 years to treat this debilitating disease, continuing Janssen's 60-plus-year history and commitment to research that make a difference for people ...
Janssen Submits Esketamine Nasal Spray New Drug Application to U.S. FDA for Treatment-Resistant Depression
Sep 04, 2018 United States If approved, esketamine nasal spray would provide the first new mechanism of action in 30 years to treat this debilitating mental illness 1, 2 TITUSVILLE, N.J., Sept. 4, 2018 -- The Janssen Pharmaceutical Companies of Johnson ...
New Data Highlights the Value of SPRAVATO™ (esketamine) CIII Nasal Spray, the First New Antidepressant in Decades that Works Differently for Adults with Treatment-Resistant Depression (TRD)[1]
May 21, 2019 United States NEW ORLEANS, May 21, 2019 -- The Janssen Pharmaceutical Companies of Johnson & Johnson presented a new cost-efficiency analysis at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting ...